ChristopherGallagherMD

PubMed

• 2 citations
  P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2- Metastatic Breast Cancer-A Podcast.
  Adam Brufsky, Christopher Gallagher
  Targeted Oncology. 2023-05-01
• 16 citations
  BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breas...
  Bryan P Schneider, Guanglong Jiang, Tarah J Ballinger, Fei Shen, Christopher Chitambar
  Journal of Clinical Oncology. 2022-02-01
• 19 citations
  Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC.
  Sagar Sardesai, Alexandra Thomas, Christopher Gallagher, Filipa Lynce, Yvonne L. Ottaviano
  Clinical Cancer Research. 2021-11-01

Journal Articles

• Survival in Patients with HER2-POSITIVE Early Stage Breast Cancer Treated with Adjuvant Trastuzumab in Clinical Practice  
  Gallagher CM, More K, Masaquel, et al, SpingerPlus, 1/1/2016
• Delay in Trastuzumab Initiation Leads to Decreased Overall Survival in Patients with HER2+ Early Stage Breast Cancer  
  Gallagher CM, More K, Masaquel A , et. Al, Breast Cancer Res Treat, 1/1/2016
• Survival and Racial Differences of Non-Small Cell Lung Cancer in the United States Military  
  Brzezniak C, Satran-Hoang S, Goetz H, Reyes C, Gunuganti A, Gallagher C, Carter C, J Gen Intern Med, 1/1/2015
• Medical Management of patients with multiple organ dysfunction arising from acute radiation syndrome  
  Jackson WL, Gallagher CM, Myhand RC, Waselenko JK, British Journal of Radiology, 1/1/2005
• Presentation and management of venous aneurysms  
  Gillespie DL, Villavicencio JL, Gallagher CM, Journal of Vascular Surgery, 1/1/1997
• Join now to see all

Abstracts/Posters

• Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy:...
  Khoury K, Isaacs C, Gatti-Mays ME, Donahue RN, Schlom J, Wang H, Gallagher C, Graham D, Warren R, Dilawari A, Swain SM, Pohlmann PR, Lynce F, San Antonio Breast Cancer Symposium, 1/7/2018
• SAFE-HEaRt: A pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function
  Lynce F, Barac A, Geng X, Dang C, Yu A, Smith KL, Gallagher C, Pohlmann PR, Nunes M, Herbolsheimer P, Warren R, Srichai B, Hofmeyer M, Cunningham A, Timothee P, Asch F..., J Clin Oncol, 1/1/2018
• Increasing participation in research - breast cancer (Inspire-BrC)
  Swain S, Robinson BN, Newman AF, Tefera E, Herbolsheimer P, Nunes R, Gallagher C, Randolph-Jackson P, Omogbehin A, Dilawari A, Pohlmann P, Mohebtash M, Ottaviano Y, Mo..., San Antonio Breast Cancer Symposium, 1/5/2016
• PALINA: A phase II safety study of palbociclib in combination with letrozole in African American women with hormone receptor positive HER2 negative advanced breast cancer
  Lynce F, Shajahan-Haq A, Cai L, Graham D, Gallagher C, Mohebtash M, Kamugisha L, Novielli N, Castle J, Forero A, Isaacs C, San Antonio Breast Cancer Symposium, 1/5/2016
• Delay in Trastuzumab Initiation Leads to Decreased Overall Survival in Patients with HER2+ Early Stage Breast Cancer
  Gallagher C, More K, Masaquel A , et. Al, San Antonio Breast Cancer Symposium, 1/9/2014
• Overall Survival in Patients with HER2+ Early-Stage Breast-Cancer Treated with Trastuzumab in the US Department of Defense Practice Setting
  Gallagher C, More K, Kamath T, et al, ISPOR 17th Annual European Congress, Amsterdam, Netherlands, 1/8/2014
• Relapse impact on overall survival in trastuzumab-treated women with HER2+ early stage breast cancer
  Gallagher C, More K, Masaquel A, et al, American Society of Clinical Oncology 2014 Annual Meeting; J Clin Oncol, 1/1/2014
• Discordance Rate Between 2 Tests Used to Diagnose Patients with HER2-Overexpressing Breast Cancer
  Gallagher C, More K, Hu H, Sicignano N, Masaquel A, Kamath T, Brammer M, Shriver C, Goehring E Jr, Kapasi A, Jones JK, Academy of Managed Care Pharmacy 26th Annual Meeting, Tampa, FL, 1/1/2014
• Non-Small Cell Lung Cancer (NSCLC) in the United States Department of Defense
  Carter C, Satram-Hoang S, Gunuganti A, Reyes C, Goertz HP, Gallagher C, 15th World Conference on Lung Cancer, Sydney, Australia, 1/29/2013
• Racial/Ethnic Variation Among Non-Small Cell Lung Cancer (NSCLC) Patients in the United States Department of Defense
  Carter C, Satram-Hoang S, Brzezniak C, Gunuganti A, Reyes C, Goertz HP, Gallagher C, 15th World Conference on Lung Cancer, Sydney, Australia, 1/29/2013
• Racial/ethnic differences in breast cancer survival by inflammatory and hormonal receptor states: an analysis of the Surveillance, Epidemiology, and End Results data
  Zahm JK, Jatoi SH, McGlynn KA, Gallagher C, Enewold L, Schairer C, Shriver CD, Zhu K, Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research, National Harbour, MD, 1/27/2013
• HER2+ and HER2- luminal B subtypes have similar overall survival and histologic grade distributions
  Chen H, Kovatich AJ, Fantacone-Campbell JL, Hooke JA, Kvecher L, Kovatich AW, Gallagher CM, Hueman MT, Hyslop T, Mural RJ, Shriver CD, Rui H, and Hu H, The 36th San Antonio Breast Cancer Symposium, San Antonio, TX, 1/10/2013
• Severe tumor lysis in refractory Burkitt's Lymphoma after treatment with R-EPOCH
  Shumway NM, Gallagher CM, Regional American College of Physicians' Meeting, 1/1/2003
• Inadvertant intravenous Bacillus Calmette-Guerin converted near-CR to CR in a patient with relapsed multiple myeloma
  Gallagher CM, Straight TM, Drabick J, Blood, 1/1/2003
• Tuberculous empyema necessitans presenting as low back pain and lower extremity weakness
  Klote M, Gallagher CM, Frizzell E, Oglesby R, Regional American College of Physicians' Meeting, 1/1/1999
• Neutrophil priming state predicts capillary leak after gut ischemia in rats
  Miner T, Connor C, Gallagher CM, Tavaf-Motamenm H, Shea-Donahue T, Gary Wratten Surgical Symposium, Seattle, WA, 1/1/1999
• Constitutive nitric oxide synthase activity increases intestinal mucosal injury after ischemia-reperfusion in the rat intestine
  Gallagher CM, Tavaf-Motamen H, Conner WC, Surgical Forum, American College of Surgeons, 1/1/1998
• Mucosal protection with exaggerated inflammation after repeated intestinal ischemia-reperfusion in rats
  Miner T, Tavaf-Motamen H, Gallagher CM, Gastroenterology, 1/1/1998
• Two-hit model of intestinal ischemia-reperfusion: timing not severity of injury causes gut and lung injury
  Gallagher CM, Conner WC, Tavaf-Motamen H, Gastroenterology, 1/1/1998
• Role of enteric nerves in the adaptation of the small intestine after ischemia-reperfusion injury in the rat
  Conner WC, Gallagher CM, Tavaf-Motamen H, Gastroenterology, 1/1/1998
• Join now to see all

Lectures

• Update on Adjuvant Therapy for Early Stage Breast Cancer 
  Walter Reed National Military Medical Center - 1/1/2012
• Adopting New Standards of Cancer Care: Challenges and Opportunities 
  Lapidus Cancer Institute, Sinai Hospital of Baltimore, Baltimore, MD - 1/1/2011
• One Step Forward, One Step Back: The Utility of Pharmacogenomics and Bisphosphonates in Early Stage Breast Cancer 
  Farmington, PA - 1/1/2011
• Update on PARP Inhibition: Emerging Data in Metastatic Breast Cancer 
  Bethesda, MD - 1/1/2010
• The Prognostic and Predictive Value of Genomic Testing in Breast and Colon Cancer 
  Providence Hospital, Washington, DC - 1/1/2010
• Update in Breast Cancer for the Primary Care Provider 
  Dilorenzo Tricare Health Clinic (Pentagon) - 1/1/2010
• Role of Oncotype DX in Lymph Node Positive Breast Cancer 
  National Naval Medical Center - 1/1/2010
• Update in Chemotherapeutic Agents 
  1/1/2010
• Breast Cancer Update in Medical Oncology: Diminishing role for anthracyclines, tamoxifen genotyping, and PARP1 inhibitors 
  Farmington, PA - 1/1/2009
• Role of Ovarian Ablation in the Management of Early Stage Breast Cancer 
  1/1/2009
• Role of Ovarian Ablation in the Management of Breast Cancer 
  1/1/2007
• Role of Genomic Identifiers in the Management of Early Stage Breast Cancer 
  Gettysburg, PA - 1/1/2007
• Update: Adjuvant and Neoadjuvant Therapy for Operable Breast Cancer 
  Georgetown University, Washington, DC - 1/1/2007
• Chemotherapy for Breast Cancer 
  1/1/2006
• Endocrine Therapies for Early Stage Breast Cancer 
  Walter Reed Army Medical Center, Washington, DC - 1/1/2006
• Neoplasms of the Leptomeninges 
  Walter Reed Army Medical Center, Washington, DC - 1/1/2005
• Update: Adjuvant Hormonal Therapy for Breast Cancer 
  Walter Reed Army Medical Center, Washington, DC - 1/1/2005
• Constitutive Nitric Oxide Synthase Activity Increases Intestinal Mucosal Injury after Ischemia-Reperfusion in Rat Intestine 
  Washington, DC - 1/1/1998
• Two Hit Model of Intestinal Ischemia-Reperfusion Injury: Nitric Oxide Protects against Mucosal Injury after the Second Hit 
  Washington, DC - 1/1/1998
• Two-Hit Model of Gut Ischemia-Reperfusion: Timing of Second Hit Causes Acute Lung Injury 
  1/1/1998
• Enteric Nerves Protect Against Gut Ischemia-Reperfusion in the Rat 
  1/1/1998
• Flow Cytometry Accurately Measures Both Quantitative and Qualitative Oxidative Burst Potential of Circulating Neutrophils after Intestinal Ischemia-Reperfusion 
  1/1/1998
• The Priming State of the Circulating Neutrophil (PMN) Predicts Lung Injury after Gut Ischemia-Reperfusion 
  1/1/1998
• Extremity Venous Aneurysms: An Institutional Case Series and Literature Review 
  Breckinridge, CO - 1/1/1996
• Join now to see all

Other

• ASCO/CAP Guidelines To Determine ER Status May Need Rehaul 
  Gallagher CM, General Surgery News
  http://www.generalsurgerynews.com/ViewArticle.aspx?d=In+the+News&d_id=69&i=June+2012&i_id=857&a_id=21046
  1/1/2012
• A Sea Change for Military Medicine: Walter Reed Joins Navy Medical Center in Bethesda 
  Gallagher CM, U.S. Medicine
  http://www.usmedicine.com/articles/a-sea-change-for-military-medicine-walter-reed-joins-navy-medical-center-in-bethesda.html?page=2
  1/1/2011